Revance Therapeutics, Inc.

Revance Therapeutics, Inc.

RVNC
Revance Therapeutics, Inc.US flagNASDAQ Global Market
3.65
USD
- -
- -
381.02MMarket Cap
Revance Therapeutics, Inc.
RVNC
(NASDAQ Global Market)

Recent

price

3.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
0.08
0.1
0.03
0.02
0.01
0.01
0.01
0.1
0.01
0.26
1.15
1.82
2.77
2.47
Revenue per Share
-6.25
-8.12
-3.75
-3.24
-3.02
-3.18
-4.01
-3.94
-3.67
-4.86
-4.17
-4.9
-3.83
-1.84
Basic EPS, GAAP
-3.98
-5.47
-3.06
-3.2
-2.42
-2.25
-3.25
-11.59
-2.52
-3.15
-3.44
-2.71
-2.64
-1.95
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-22.3
-30.42
-11.04
-13.34
-13.65
-14.99
-18.01
-18.93
-19.42
-19.41
-20.71
-24.13
-24.57
-22.07
Book Value per Share
-21.66
-30.2
-8.88
9.1
10.4
6.3
8.93
4.03
5.19
2.69
-1.98
-1.37
-1.91
-1.71
Tangible Book Value per Share
7
7
18
19
24
28
30
36
43
58
68
73
85
100
Basic Weighted Avg Shares
1
1
1
- -
- -
- -
- -
4
- -
15
78
133
234
247
Sales/Revenue/Turnover
-4,979.89
-6,023.15
-6,195.3
-13,590.08
-24,105.67
-26,385.33
-44,846.18
-3,824.99
-39,820.58
-1,782.46
-353.06
-205.31
-95
-67.62
Operating Margin (%)
2
2
2
2
2
1
1
2
3
10
20
39
14
6
Depreciation Expense
-45
-58
-52
-63
-73
-89
-121
-143
-159
-282
-281
-356
-324
-184
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-8,054.4
-8,125.38
-8,500.49
-16,427.42
-24,492
-29,756.67
-46,025.57
-3,823.22
-38,602.66
-1,840.71
-361.59
-268.87
-138.43
-74.67
Profit Margin (%)
21
-113
-43
162
242
173
264
176
256
389
179
299
250
250
Working Capital
64
11
3
1
5
2
- -
- -
26
208
320
414
468
456
LT Debt
-155
-217
-158
176
253
177
269
146
225
374
68
13
-152
-163
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
12
32
27
LT Borrowings
425
423
421
LT Finance Leases
39
37
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
104
105
105
Market Capitalization
430
242
519

Working Capital

FRC

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
370
350
330
Cash, Cash Equivalents & STI
277
232
184
Accounts Receivable, Net
30
36
48
Inventories
50
68
85
Total Current Liabilities
69
94
80
Payables & Accruals
27
29
35
ST Debt
12
32
27
Deferred Revenue
10
10
6

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-153.81%
-269.14%
-1,303.21%
Free Cash Flow
41.8%
3.69%
13.57%
Net Income, GAAP
21.76%
21.22%
-9.1%
Sales/Revenue/Turnover
- -
815.27%
76.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
25
28
29
50
133
2023
46
54
54
70
234
2024
52
65
60
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.94
-0.88
-1.17
-1.82
-4.9
2023
-0.74
-0.8
-1.63
- -
-3.83
2024
-0.58
-0.36
-0.37
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Business
Revance Therapeutics, Inc. (RVNC) is a biotechnology company that develops, manufactures, and commercializes neuromodulators and related products for aesthetic and therapeutic indications. The company offers DAXXIFY (daxibotulinumtoxinA-lanm) for injection to treat glabellar lines and cervical dystonia; the RHA Collection of hyaluronic acid dermal fillers distributed in partnership with Teoxane SA; a portfolio of skincare products including the number-one selling mineral sunscreen brand and skin barrier strengthening formulas; the number-one microneedling device in the US; a platelet rich plasma system; and therapeutics advancing treatments for movement disorders. Revance operates globally with products available in the United States and through partnerships such as Viatris for a biosimilar to onabotulinumtoxinA and Fosun for DAXXIFY commercialization in China. Founded in 1999 and headquartered in Nashville, Tennessee, Revance completed its acquisition by Crown Laboratories in February 2025, uniting the companies under the REVANCE brand to expand its aesthetics, skincare, and therapeutics portfolio; the firm also reached a milestone of distributing one million vials of DAXXIFY in the US and launched the Teoxane RHA Collection with Mepivacaine anesthetic.

Company News

APIChatGPT
  • REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

  • Revance Announces Blue Lizard® Australian Sunscreen Times Square Takeover to Celebrate National Sunscreen Day

  • REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

  • Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky

  • Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNC

  • RVNC DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNC

  • Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)

  • Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)

  • Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC

  • FINAL REMINDER RVNC DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Revance Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit

  • Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC

  • Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC

  • March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNC

  • RVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNC

  • Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & Korsinsky

  • Deadline Soon: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

  • Revance Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – RVNC

  • Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline

  • Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC

  • Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class Action - RVNC